Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy

Cell Cycle

Volumn 8, Issue 11, 2009, Pages 1654-1658

  Witkiewicz, Agnieszka K ^a,b,c   Casimiro, Mathew C ^a,b   Dasgupta, Abhijit ^a,c   Mercier, Isabelle ^a,b   Wang, Chenguang ^a,b   Bonuccelli, Gloria ^a,b   Jasmin, Jean François ^a,b   Frank, Philippe G ^a,b   Pestell, Richard G ^a,b   Kleer, Celina G ^d   Sotgia, Federica ^a,b   Lisanti, Michael P ^a,b,e  

^a Jefferson Stem Cell Biology and Regenerative Medicine Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biomarkers; Breast cancer; Cancer associated fibroblasts; Caveolin 1; Prognosis; Stroma; Treatment stratification

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CAVEOLIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; TAMOXIFEN;

BREAST CANCER; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER THERAPY; CELL CYCLE PROGRESSION; FIBROBLAST; HUMAN; LYMPH NODE METASTASIS; ONCOGENE H RAS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STROMAL CLASSIFICATION;

EID: 66749147690     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.11.8544     Document Type: Review

References (34)

1. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008; 26:3153-3158
2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41:154-161
3. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers. Am J Pathol 2009; 174:2023-2034
4. Lisanti MP, Scherer P, Tang Z-L, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: A signalling hypothesis. Trends In Cell Biology 1994; 4:231-235 (Pubitemid 24190653)
5. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, A family of scaffolding proteins for organizing "pre-assembled signaling complexes" at the plasma membrane. J Biol Chem (Mini-review) 1998; 273:5419-5422
6. Sotgia F, Williams TM, Cohen AW, Minetti C, Pestell RG, Lisanti MP. Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/beta-catenin signaling. Cell Cycle 2005; 4:1808-1816 (Pubitemid 41827328)
7. Li J, Hassan GS, Williams TM, Minetti C, Pestell RG, Tanowitz HB, et al. Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation. Cell Cycle 2005; 4:1817-1825 (Pubitemid 41827329)
8. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92:1381-1385
9. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17:6633-6648 (Pubitemid 28521797)
10. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998; 16:1391-1397 (Pubitemid 28151846)
11. Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: Role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 2004; 279:24745-24756 (Pubitemid 38725342)
12. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Allen KG, et al. Human Breast Cancer-Associated Fibroblasts (CAFs) Show Caveolin-1 Downregulation and RB Tumor Suppressor Functional Inactivation: Implications for the Response to Hormonal Therapy. Cancer Biol Ther 2008; 7:1212-1225
13. -/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174:746-761
14. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, et al. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-like Mammary Lesions. Am J Pathol 2009; 174:1172-1190
15. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, et al. Stromal and Epithelial Caveolin-1 Both Confer a Protective Effect Against Mammary Hyperplasia and Tumorigenesis: Caveolin-1 Antagonizes Cyclin D1 Function in Mammary Epithelial Cells. Am J Pathol 2006; 169:1784-1801
16. Ronnov-Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 2009; 15:5-13.
17. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson M, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174;2035-2043
18. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factorbeta receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20:713-719
19. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin-1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58:2854-2865
20. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006; 114:912-920 (Pubitemid 44337134)
21. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis J, et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res 2004; 63:747-755 (Pubitemid 39078689)
22. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007; 66:551-553 (Pubitemid 46580482)
23. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113-1116 (Pubitemid 43825461)
24. Derk CT. Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol 2007; 26:1615-1619
25. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337-347
26. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10:201.
27. Gaggioli C. Collective invasion of carcinoma cells: when the fibroblasts take the lead. Cell Adh Migr 2008; 2:45-47
28. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007; 9:1392-1400 (Pubitemid 350201752)
29. Dontu G. Breast cancer stem cell markers - the rocky road to clinical applications. Breast Cancer Res 2008; 10:110.
30. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11:1154-1159
31. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10:53.
32. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715
33. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, et al. Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells. Cancer Res 2009; 69:2887-2895
34. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009; 14:29-43.